SERDOLECT 4 MG

البلد: إسرائيل

اللغة: الإنجليزية

المصدر: Ministry of Health

العنصر النشط:

SERTINDOLE

متاح من:

LUNDBECK ISRAEL LTD.

ATC رمز:

N05AE03

الشكل الصيدلاني:

FILM COATED TABLETS

تركيب:

SERTINDOLE 4 MG

طريقة التعاطي:

PER OS

نوع الوصفة الطبية :

Required

المصنعة من قبل:

H. LUNDBECK A/S, DENMARK

المجموعة العلاجية:

SERTINDOLE

المجال العلاجي:

SERTINDOLE

الخصائص العلاجية:

For the treatment of schizophrenia. Due to cardiovascular safety concerns serntidole should only be used for patients intolerant to at least one other anti-psychotic agent. Sertindole should not be used in emergency situations for urgent relief of symptoms in acutely disturbed patients.

تاريخ الترخيص:

2022-09-30

نشرة المعلومات

[לוגו מדינת ישראל] [http://www.gov.il/]
[http://www.gov.il/] [לוגו משרד הבריאות] [לוגו משרד
הבריאות] [*5400]
[http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx]
[http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx]
הציבור הרחב עסקים ומוסדות עובדים
בבריאות חפש מידע
תפריט *
[סגירה]
סגור *
דף הבית [http://www.health.gov.il/] *
אודות *
אודות המשרד
[http://www.health.gov.il/About/Pages/about_us.aspx] *
תוכנית עבודה
[http://www.health.gov.il/About/Pages/Agenda.aspx] *
תקציב המשרד
[http://www.health.gov.il/About/Pages/budget.aspx] *
תרשים מבנה ארגוני
[http://www.health.gov.il/About/Pages/OrganizationalStructureDiagram.aspx] *
בעלי תפקידים
[http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx] *
יחידות המשרד
[http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx] *
לשכות הבריאות
[http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx?tab=3] *
אמנת שירות
[http://www.health.gov.il/About/sla/Pages/default.aspx] *
אותות ופרסים
[http://www.health.gov.il/About/Awards/Pages/mifal.aspx] *
פרוייקטים תשתיתיים
[http://www.health.gov.il/About/projects/shared_medical_info/Pages/default.aspx] *
דרושים
[http://www.health.gov.il/About/Careers/Pages/default.aspx] *
מנכ"לי משרד הבריאות לדורותיהם
[http://www.health.gov.il/About/Pages/GeneralManegerHistory.aspx] *
יחידות המשרד *
יחידות המשרד
[http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx] *
לשכות הבריאות
[http://www.health.gov.il/UnitsOffice/LB/Pages/default.aspx] *
וועדות ומועצות
[http://www.health.gov.il/Services/Committee/Pages/CommitteeList.aspx] *
נושאים *
בריאות הנפש
[http://www.health.gov.il/Subjects/mental_health/Pages/default.aspx] *
בריאות הסביבה
[http://www.health.gov.il/Subjects/Environmental_Health/

خصائص المنتج

קנ הז ןולע טמרופ
ב
רשואו קדבנ ונכותו תואירבה דרשמ י"ע ע
ינויב
2015
PRISCRIBING INFORMATION
1.
NAME OF THE MEDICINAL PRODUCT
SERDOLECT 4MG
SERDOLECT 16MG
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 4 mg tablet contains: sertindole 4 mg
Each 16 mg tablet contains: sertindole 16 mg
Excipients:
Each 4 mg film-coated tablet contains 60.78 mg lactose monohydrate.
Each 16 mg film-coated tablet contains 95.08 mg lactose monohydrate.
See section 4.4.
For a full list of excipients see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablets.
Description of the tablets:
4 mg: Oval, yellow, biconvex film-coated tablets marked with “S4”
on one side.
16 mg: Oval, rose, biconvex film-coated tablets marked with “S16”
on one side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Sertindole is indicated for the treatment of schizophrenia.
Due to cardiovascular safety concerns, sertindole should only be used
for patients intolerant to at
least one other antipsychotic agent.
Sertindole should not be used in emergency situations for urgent
relief of symptoms in acutely
disturbed patients.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Sertindole is administered orally once daily with or without meals. In
patients where sedation is
required, a benzodiazepine may be co-administered.
Page 1 of 12
Titration
All patients should be started on sertindole 4 mg/day. The dose should
be increased by increments of
4 mg after 4-5 days on each dose until the optimal daily maintenance
dose, within the range of
12-20 mg, is reached. Due to the
α
1
-blocking activity of sertindole, symptoms of postural
hypotension may occur during the initial dose-titration period. A
starting dose of 8 mg or a rapid
increase in dose carries a significantly increased risk of postural
hypotension.
Maintenance
Dependent on individual patient response, the dose may be increased to
20mg/day. Only in
exceptional cases should the maximum dose of 24 mg be considered, as
clinical trials have not
demonstrated consisten